PhytoZon Claims Could Land American Dream In Regulatory Nightmare
This article was originally published in The Tan Sheet
NAD refers questions about PhytoZon claims to FDA and FTC after American Dream declines to submit evidence in a challenge by the Council for Responsible Nutrition. The multi-level marketer refers NAD attorneys to its website with links to around 500 studies, which look at ingredients and not the product.
You may also be interested in...
Dietary supplement multi-level marketer American Dream says it will comply with NAD's recommendations even though "it disagrees with the standard NAD applied to its claims for its dietary supplement."
Latest warnings also include second and third businesses in US cannabidiol and hemp sector found making unlawful claims for treating and preventing COVID-19. Four of five firms warned apparently responded by removing violative claims from websites and social media posts.
OTC Decisions In March: Lumify Single-Use, Aleve Arthritis-Grip Cap Labeling, And More Prilosec, Mucinex Copies
Total of CDER decisions during March on OTC applications was down from January and February and also were less substantial for the marketplace. After approving OTC switches in first two months, March decisions for newly available OTCs were limited to additional guaifenesin/pseudoephedrine and omeprazole products offered as private label/store brand alternatives to brands.